Biolase, Inc.
BIOLQ Healthcare Medical Devices
Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BIOLQ
Biolase, Inc. (BIOLQ) EV/Sales
As of 15 October 2026, Biolase, Inc. (BIOLQ) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from 0.2× (November 2023) to 4.3× (April 2021); the current reading is higher than 25% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 0.2× | (39.61%) |
| FY2022 | 0.3× | (71.63%) |
| FY2021 | 1.1× | (0.40%) |
| FY2020 | 1.1× | 98.09% |
| FY2019 | 0.5× | (5.33%) |
| FY2018 | 0.6× | 18.28% |
| FY2017 | 0.5× | (68.54%) |
| FY2016 | 1.5× | 93.97% |
| FY2015 | 0.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 0.3× | 29.40% |
| Jun 2024 | 0.3× | 13.80% |
| Mar 2024 | 0.2× | 24.67% |
| Dec 2023 | 0.2× | 5.42% |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IVF INVO Fertility, Inc compare | −0.3× |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| BIOLQ Biolase, Inc. | 0.3× |
| AFIB Acutus Medical, Inc. compare | 0.9× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. compare | 2.1× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| ADGM Adagio Medical Holdings, Inc. compare | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)